Tags

Type your tag names separated by a space and hit enter

Projected coronary heart disease risk benefit with ezetimibe.
Atherosclerosis 2005; 179(2):375-8A

Abstract

Low density lipoprotein (LDL) cholesterol and total cholesterol (TC) are the primary clinical parameters of interest for any cholesterol intervention. Clinicians are interested in how the reduction of these lipid parameters as well as increases in high density lipoprotein (HDL) relate to changes in coronary heart disease (CHD) risk. The objective of this analysis was to estimate the additional CHD risk reduction that could potentially be provided by co-administration of ezetimibe with statin therapy. Data from four double-blind placebo controlled clinical trials were used to predict the level of CHD risk reduction that might be achieved by co-administration of ezetimibe with statin therapy when compared to those receiving statin as monotherapy. Patients without a previous history of CHD were included in the analysis. Projected CHD risk reduction was calculated as percent change in projected CHD risk from baseline to 12 weeks based on observed lipid levels at those time points. For all the studies combined greater reductions in percent change in 5-year CHD risk were observed for patients receiving ezetimibe and statin as co-therapy, 53.4%, when compared to those receiving statin alone, 39.7%. Co-administration of ezetimibe with statin therapy provides an additional 13.7% reduction in predicted 5-year CHD risk when compared to statin monotherapy. Reductions in 5-year CHD risk for each of the statin studies ranged from 16.1% for lovastatin to 9.8% for atorvastatin. Co-administration of ezetimibe with statins could significantly reduce CHD events in patients with primary hypercholesterolemia.

Authors+Show Affiliations

Merck Research Laboratories, Merck and Co., Inc.-BL2-3, 10 Sentry Parkway, Blue Bell, West Point, PA 19422, USA. glenn.davies@merck.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15777556

Citation

Davies, Glenn M., et al. "Projected Coronary Heart Disease Risk Benefit With Ezetimibe." Atherosclerosis, vol. 179, no. 2, 2005, pp. 375-8.
Davies GM, Cook JR, Erbey J, et al. Projected coronary heart disease risk benefit with ezetimibe. Atherosclerosis. 2005;179(2):375-8.
Davies, G. M., Cook, J. R., Erbey, J., Alemao, E., & Veltri, E. P. (2005). Projected coronary heart disease risk benefit with ezetimibe. Atherosclerosis, 179(2), pp. 375-8.
Davies GM, et al. Projected Coronary Heart Disease Risk Benefit With Ezetimibe. Atherosclerosis. 2005;179(2):375-8. PubMed PMID: 15777556.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Projected coronary heart disease risk benefit with ezetimibe. AU - Davies,Glenn M, AU - Cook,John R, AU - Erbey,John, AU - Alemao,Evo, AU - Veltri,Enrico P, Y1 - 2004/12/15/ PY - 2004/03/29/received PY - 2004/09/16/revised PY - 2004/10/19/accepted PY - 2005/3/22/pubmed PY - 2005/6/29/medline PY - 2005/3/22/entrez SP - 375 EP - 8 JF - Atherosclerosis JO - Atherosclerosis VL - 179 IS - 2 N2 - Low density lipoprotein (LDL) cholesterol and total cholesterol (TC) are the primary clinical parameters of interest for any cholesterol intervention. Clinicians are interested in how the reduction of these lipid parameters as well as increases in high density lipoprotein (HDL) relate to changes in coronary heart disease (CHD) risk. The objective of this analysis was to estimate the additional CHD risk reduction that could potentially be provided by co-administration of ezetimibe with statin therapy. Data from four double-blind placebo controlled clinical trials were used to predict the level of CHD risk reduction that might be achieved by co-administration of ezetimibe with statin therapy when compared to those receiving statin as monotherapy. Patients without a previous history of CHD were included in the analysis. Projected CHD risk reduction was calculated as percent change in projected CHD risk from baseline to 12 weeks based on observed lipid levels at those time points. For all the studies combined greater reductions in percent change in 5-year CHD risk were observed for patients receiving ezetimibe and statin as co-therapy, 53.4%, when compared to those receiving statin alone, 39.7%. Co-administration of ezetimibe with statin therapy provides an additional 13.7% reduction in predicted 5-year CHD risk when compared to statin monotherapy. Reductions in 5-year CHD risk for each of the statin studies ranged from 16.1% for lovastatin to 9.8% for atorvastatin. Co-administration of ezetimibe with statins could significantly reduce CHD events in patients with primary hypercholesterolemia. SN - 0021-9150 UR - https://www.unboundmedicine.com/medline/citation/15777556/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0021-9150(04)00567-2 DB - PRIME DP - Unbound Medicine ER -